More than a decade ago, Alzheimer’s vaccines appeared in clinical trials — but failed. Now several companies are gearing up to test the next…
A person who struggles with tasks they’ve been doing for years or asks the same question over and over again may be showing the…
Scientists developed new brain cells to replace those lost in Parkinson’s. Early trials showed they’re safe — now, larger human trials are on the…
Your genetics could make you more vulnerable to the side effects of the new class of Alzheimer’s drugs. Carrying two copies of the ApoE4…
Treatment with a powerful magnet is one of the newest experimental therapies being used to try to turn back the clock on Alzheimer’s disease….
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
Could a headset with flashing lights and sounds stimulate brain waves and treat Alzheimer’s? Cognito’s Phase 3 trial on such a device is trying…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
ApoE4, a genetic variation sometimes referred to as the “Alzheimer’s gene,” is one of the most influential genetic risk factors for developing Alzheimer’s disease….
A Trump executive order has banned DEI initiatives across the federal government. Scientists say the move could undermine trial diversity and derail the quest…
Would you still participate in an Alzheimer’s clinical trial if you found out that because of your genetics, you were more vulnerable to serious…
Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are changeable — they…
A recent Science investigation found that Eliezer Masliah, one of the world’s leading Alzheimer’s and Parkinson’s researchers, engaged in research misconduct over the course…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…